Resource Logo
Reuters New Media

Japan Tobacco applies to sell anti-HIV tablet in Japan


TOKYO, Dec 6 (Reuters) - Japan Tobacco Inc said on Thursday it has applied to sell an anti-HIV drug treatment in Japan.

If approved by the Health Ministry, it would be the only once-daily single-tablet regimen for HIV infection in Japan, it said.

The drug contains JT's compound elvitegravir, which is used in Gilead Sciences Inc's Stribild regimen, approved by the U.S. Food and Drug Administration in August 2012.

JT licensed elvitegravir to Gilead in 2005, giving Gilead exclusive rights to develop and commercialise the drug worldwide outside Japan.

(Reporting by Mayumi Negishi; Editing by Michael Watson)


Copyright © 2012 -Reuters New Media, Publisher. All rights reserved to Reuters .Ltd. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Information in this article was accurate in December 6, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.